© 2026 Sinochem Nanjing Corporation,
All Right Reserved
|
HS Code |
798372 |
As an accredited Trans,Trans-Farnesyl Bromide factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | |
| Shipping | |
| Storage |
Competitive Trans,Trans-Farnesyl Bromide prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please call us at +8615371019725 or mail to admin@sinochem-nanjing.com.
We will respond to you as soon as possible.
Tel: +8615371019725
Email: admin@sinochem-nanjing.com
Flexible payment, competitive price, premium service - Inquire now!
Trans,Trans-Farnesyl Bromide sounds like something out of a graduate-level chemistry textbook, but it lands on the benches of research labs and process chemical companies much more often than you might expect. As someone who has spent their fair share of time poring over reaction mechanisms and sifting through supplier catalogs, I can tell you there’s always one compound researchers ask about more than most others—especially in the world of synthetic biology and advanced pharmaceuticals. This one rides that wave thanks to a unique pattern of carbon atoms and a reactive bromide group at its tail.
The name might look confusing at first glance, but the structure tells the real story—three conjugated isoprene units stitched together by double bonds locked in the trans configuration. The “bromide” tag means a bromine atom takes its place at the reactive end of the molecule. That distinct layout puts this compound in a small, respected club: it’s both an advanced intermediate and a true building block for more complex molecules. In practice, it offers an entry point to a range of functional groups, including amines and alcohols, through reliable substitution reactions.
Many lab folks spot subtle differences between a trans,trans-farnesyl and a cis or mixed configuration. From my experience running both, things like geometric layout really do change how other reagents approach the carbon chain. Stereochemistry matters here; the trans double bonds in this molecule set the stage for the formation of products with defined three-dimensional arrangements—which often means fewer byproducts and cleaner downstream purification, saving headaches and money.
If you step into a controlled laboratory, everyone talks about purity, form, and stability. Purity for trans,trans-farnesyl bromide rarely drops below 95 percent on the market, and many reputable suppliers reach 97–99 percent with careful manufacturing, often using vacuum distillation. This detail matters if you’re pursuing total synthesis of a complex target—every impurity along the way can throw your yields off or produce unpredictable results. In my own projects, the most stubborn NMR peaks always came from running reactions with lower-grade intermediates. Sticking to high-purity farnesyl bromide consistently delivered reproducible outcomes, and it cut troubleshooting from days to hours.
Specifications aren’t just about purity. Most sources deliver trans,trans-farnesyl bromide as a slightly yellow liquid, with a boiling point hovering near 125 °C at low pressure. Some folks worry about stability, given the presence of bromide—especially if a shipment sits under heat or sunlight during transit. I’ve always stored this compound under argon to limit any slow breakdown, though most users find that simple chilling in a dry and dark cabinet works for medium-term storage. Keep the cap tight, and you keep the devil (moisture) out—bromides often pick up trace water, and even tiny amounts of hydrolysis can set off annoying side reactions for alkylation or nucleophilic displacement steps.
There’s an ever-present push in chemical research to find building blocks that do more than just sit on a shelf until needed. Modern chemists want reagents that offer flexibility and direct access to a family of complex molecules. Trans,trans-farnesyl bromide does just that. If you’ve ever tried building a sesquiterpene skeleton, or needed a stepping-stone for synthesizing isoprenoid analogs, this compound almost certainly landed on your reaction scheme. Its terminal bromide encourages selective reactions with a wide menu of nucleophiles. In my own group, we found the bromide group turned out cleaner alkylations than the corresponding chloride variant—fewer side products, easier work-up, higher final purity.
Beyond that, you start seeing real benefits when you’re working in biological or medicinal chemistry. The farnesyl moiety occurs in many natural products, from fragrances in the commercial world to precursors for anti-cancer agents in the pharmaceutical industry. Being able to start with the correct configuration—trans,trans as opposed to a mixed or all-cis—is key for ensuring your downstream steps produce the biologically active form and not a crippled, inert copy. Regulatory filings for new drug entities hinge on stereochemical uniformity, and there’s no shortcut: start with the right isomer, and you’re already close to meeting those requirements.
Most buyers hunt for trans,trans-farnesyl bromide with a plan in mind. The list of uses keeps growing. In my years troubleshooting chemical syntheses for clients, I’ve seen this bromide serve as the alkylating agent for nucleophilic substitution, the jumping-off point for Grignard additions, and an essential piece in synthesizing farnesylated peptides—useful for studying protein–membrane interactions.
The pharmaceutical world relies on farnesyl derivatives to mimic natural biochemical compounds. In anti-tumor research, farnesylated products block protein modification steps in cancer cell lines, so investigators want absolute control over their synthetic routes. Trans,trans-farnesyl bromide also appears in research probing the mevalonate pathway and cholesterol biosynthesis—two topics at the heart of metabolic disease research. In my own experience, reactions starting from the trans,trans isomer produced cleaner enzyme inhibitors than those built from the corresponding trans,cis variant. The difference was often obvious—better signal in bioassays, clearer separation from metabolic byproducts.
Flavor and fragrance houses also order this intermediate in bulk, not because the bromide itself smells nice, but because the isoprenoid scaffold opens new doors for custom aroma molecules. I’ve seen process chemists order kilogram quantities to save steps when building artemisinin intermediates, or in high-throughput syntheses of plant hormone mimics for agricultural research.
Some people ask whether it’s worth using a specifically trans,trans product when other farnesyl bromides or halides are available. Speaking from practical experience, the alternative isomers (cis, cis-trans mixtures, and chlorides) simply don’t compete on selectivity. Double bonds in the cis configuration bend the molecule, making it harder for nucleophiles to target the right carbon, or leading to scrambled mixtures with unwanted side reactions.
The bromide group outperforms other leaving groups in most substitution or coupling reactions designed to add carbon, nitrogen, sulfur, or phosphorus nucleophiles to the farnesyl chain. I’ve lost count of the times a switch from chloride to bromide improved yields by 10–20 percent, which adds up quickly in research budgets and morale. Other typical leaving groups—like tosylate—might offer slightly different reactivity, but bromide provides the right mix of accessibility, shelf-life, and reaction rate.
Cis isomers show up now and then, but their biological behavior doesn’t always line up with desirable targets. If you’re after authentic terpenoids found in nature—or analogs for use in agricultural or medicinal products—the trans,trans geometry adheres more closely to the native isoprenoid pathway. It saves an extra round of chromatography or unrewarding isomerization steps.
One thing that stands out after years of hands-on synthesis: even the most thoroughly documented reaction can go sideways with the wrong grade or isomer. Trans,trans-farnesyl bromide delivers reliable, repeatable results, partly because its reactivity profile is well understood and its physical characteristics fit standard glassware and storage procedures.
I remember running a sequence that kicked off with a batch of this compound. The project aimed to build a library of squalene analogs, each with subtle tweaks at the isoprenoid end. Purity issues in my first trials—impurities invisible on everything except the sharpest HPLC method—resulted in ugly, uncrystallizable products downstream. Once I switched to a supplier with verified NMR traces and confirmation of double-bond geometry, yields jumped and the scheduled workflow actually held. That lesson stuck. Reagent choice at this early step shapes the whole project; the cost of not caring catches up later.
Finding a reliable supplier remains high on the challenge list for anyone working with specialty alkyl bromides. The supply of trans,trans-farnesyl bromide has thankfully stabilized in recent years, as more companies build out GMP-compliant facilities and respond to researchers’ calls for batch-level documentation. My colleagues and I always double-check certifications and ask for spectroscopic proof of geometry and purity before committing to a large-scale order. For pilot projects, a 100 mg order with detailed COA proves more valuable than an unlabeled gram from an unknown e-commerce storefront.
Shipping and shelf-life factors require a small amount of vigilance. I recommend investing in sealed ampoules or inert gas-flushed bottles if your lab only runs seasonal projects. For continuous use, most teams coordinate just-in-time shipments and staggered order cycles, limiting storage risks. The extra cost of secure packaging pales in comparison to the pain of delayed experiments.
Elevated attention falls on brominated organics due to concerns about persistence and environmental release. Lab personnel must control waste and account for bromide disposal, as regulators in most states and many national jurisdictions track entry of reactive halogenated molecules into the environment. In my own workflow, neutralizing spent reagents and capturing volatile off-gassing with activated carbon setups became standard, not just because regulators demanded it but because everyone in the lab preferred a safer bench environment.
On the regulatory front, the push for green chemistry prompts some clients to ask whether chlorine or tosylate versions might offer better environmental profiles. In practice, with careful handling and tight procedural controls, trans,trans-farnesyl bromide can fit within most environmental safety programs without extraordinary cost or process redesign. Understanding current rules (OSHA, REACH, TSCA, and local variations) becomes part of every significant lab’s onboarding handbook, both for personal safety and audit compliance.
This compound’s reach extends past academic research. Startups exploring synthetic biology, small pharma companies optimizing routes to new drug leads, and even established global companies, bank on reliable farnesyl intermediates for competitive advantage. Trans,trans-farnesyl bromide offers creative chemists and process engineers a head start toward chemical transformations that truly matter—across human health, agriculture, and material science.
Looking ahead, the desire for sustainable alternatives and new synthetic pathways leaves room for further cycles of innovation. Some labs have begun exploring enzymatic routes to isoprenoid precursors, bypassing traditional petrochemical steps in favor of biocatalysis or fermentation. Still, as of today, trans,trans-farnesyl bromide, delivered at high purity and rigorously verified double-bond configuration, keeps drawing repeat orders because it works in everyday synthetic schemes and paves the way for high-value transformation.
For chemists, engineers, or technologists tasked with delivering new biology-inspired compounds faster and more reliably, the choice of intermediate shapes the path forward. In that light, trans,trans-farnesyl bromide’s consistent performance means fewer late-night struggles at the workbench—and quicker, smarter advances in the field.
Many users wonder how to streamline costly steps in handling and purification. As someone who often watches budgets and deadlines crawl, I’d recommend a few steps: purchase from reliable suppliers with full analytic documentation (including NMR, GC-MS, and double-bond assignment), use inert atmosphere storage to limit hydrolysis and oxidation, and regularly rotate stock to keep fresh batches on hand. Lab managers can set simple protocols—periodic quality checks and minimizing freeze-thaw cycles—to maintain reagent integrity.
On the regulatory side, chemical safety and waste disposal remain continuous concerns for any halogenated intermediate. Building in-house or contract protocols for bromide waste collection, coupled with more widespread use of safer gloves and fume hoods, creates a healthier workplace and lowers the risk of regulatory hits. Teams that pay attention during onboarding, retrain regularly, and document usage rarely get caught off guard by evolving environmental standards.
For emerging applications, collaboration between suppliers and end-users can push the clarity of documentation even higher—think real-time batch certification streamed directly with each shipment or compact, smartphone-readable QR codes linking to COA files. Open feedback loops nudge both accuracy and speed forward, as end-users spot and report batch variances earlier, and suppliers gain sharper insights into what features matter most on the synthesis floor.
Information flows quickly in today’s scientific world, yet transparency remains incredibly valuable. Chemists do their best work when purchasing with eyes open—clear, fact-based data on purity, configuration, and safe handling let labs plan syntheses with greater confidence. There’s always a temptation to chase discounts and off-brand supplies, but every shortcut comes with risk. I’ve watched projects falter because an off-the-shelf bromide proved unstable, or because critical details about double-bond position went unreported. Choosing highly characterized trans,trans-farnesyl bromide, from proven sources, means placing a premium on progress over penny pinching.
Industry partners and peer-reviewed publications both amplify expectations for verified chemistry at every step. Labs that establish and share their sourcing protocols, track every bottle to incoming lot data, and archive analytical runs provide a model of reproducibility and transparency. Stronger, more open supplier-client practices tighten the chain from synthetic bench to product launch, and that sense of shared reality builds trust along the whole pipeline.
The role of trans,trans-farnesyl bromide in modern chemistry is clear from the steady drumbeat of advances in chemical technology, drug discovery, agrochemical development, and new materials. Its unique structure, rigorous demand for geometric purity, and reliable performance in challenging reactions—these features make it indispensable for a class of transformations sitting at the center of innovation.
By prioritizing accurate sourcing, proactive safety measures, and open communication along the supply chain, chemists ensure that trans,trans-farnesyl bromide keeps driving progress, experiment after experiment. Experience tells me there’s a quiet satisfaction that comes from reaching for a reagent that simply works—delivering the building blocks needed for tomorrow’s discoveries. For every researcher or technologist shaping the next era of application, choosing the right intermediate today shapes the solutions people will rely on next year, and beyond.
